Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 14
Submit an article Journal homepage
525
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine

Sangeetha Venugopala Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Abhishek Maitia Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Courtney D. DiNardoa Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Wei Qiaob Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Jing Ningb Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Sanam Loghavic Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Naval G. Davera Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Tapan M. Kadiaa Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Caitlin R. Rauschd Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Yesid Alvaradoa Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Maro Ohaniana Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Koji Sasakia Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Nicholas J. Shorta Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Koichi Takahashia Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Musa Yilmaza Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Farhad Ravandia Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Hagop M. Kantarjiana Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
&
Marina Y. Konoplevaa Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
View further author information
 show all
Pages 3501-3505 | Received 09 Jul 2021, Accepted 16 Aug 2021, Published online: 03 Sep 2021

References

  • Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606.
  • Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92(7):2322–2333.
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an International Expert Panel. Blood. 2017;129(4):424–447.
  • Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461): presented in part at the 43rd Annual Meeting of the American Society of Hematology, Orlando, FL, December 10, 2001, and published in abstract form. Blood. 2002;100(13):4325–4336.
  • Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–1924.
  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
  • DiNardo CD, Maiti A, Rausch CR, et al. 10-Day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7(10):e724–e736.
  • Maiti A, Qiao W, Sasaki K, et al. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021;96(3):282–291.
  • Maiti A, DiNardo CD, Kadia TM, et al. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: a propensity score matched analysis. Blood. 2020;136(Suppl. 1):30–33.
  • McGowan-Jordan JS, Schmid M. An international system for human cytogenomic nomenclature. Basel: S. Karger; 2016.
  • Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642–4649.
  • Döhner H, Dolnik A, Tang L, et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018;32(12):2546–2557.
  • Itzykson R, Thépot S, Berthon C, et al. Azacitidine for the treatment of relapsed and refractory AML in older patients. Leuk Res. 2015;39(2):124–130.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.